Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody

Simona Cignetto, Chiara Modica, Cristina Chiriaco, Lara Fontani, Paola Milla, Paolo Michieli, Paolo M. Comoglio, Elisa Vigna

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The kinase receptor encoded by the Met oncogene is a sensible target for cancer therapy. The chimeric monovalent Fab fragment of the DN30 monoclonal antibody (MvDN30) has an odd mechanism of action, based on cell surface removal of Met via activation of specific plasma membrane proteases. However, the short half-life of the Fab, due to its low molecular weight, is a severe limitation for the deployment in therapy. This issue was addressed by increasing the Fab molecular weight above the glomerular filtration threshold through the duplication of the constant domains, in tandem (DCD-1) or reciprocally swapped (DCD-2). The two newly engineered molecules showed biochemical properties comparable to the original MvDN30 in vitro, acting as full Met antagonists, impairing Met phosphorylation and activation of downstream signaling pathways. As a consequence, Met-mediated biological responses were inhibited, including anchorage-dependent and -independent cell growth. In vivo DCD-1 and DCD-2 showed a pharmacokinetic profile significantly improved over the original MvDN30, doubling the circulating half-life and reducing the clearance. In pre-clinical models of cancer, generated by injection of tumor cells or implant of patient-derived samples, systemic administration of the engineered molecules inhibited the growth of Met-addicted tumors.

Original languageEnglish
Pages (from-to)938-948
Number of pages11
JournalMolecular Oncology
Volume10
Issue number6
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Half-Life
Antibodies
Neoplasms
Molecular Weight
Immunoglobulin Fab Fragments
Therapeutics
Growth
Oncogenes
Peptide Hydrolases
Phosphotransferases
Pharmacokinetics
Monoclonal Antibodies
Phosphorylation
Cell Membrane
Injections
dicarboxydine

Keywords

  • Antibody
  • Cancer targeted therapy
  • Fab
  • Half-life
  • Met
  • Protein engineering

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine

Cite this

Dual Constant Domain-Fab : A novel strategy to improve half-life and potency of a Met therapeutic antibody. / Cignetto, Simona; Modica, Chiara; Chiriaco, Cristina; Fontani, Lara; Milla, Paola; Michieli, Paolo; Comoglio, Paolo M.; Vigna, Elisa.

In: Molecular Oncology, Vol. 10, No. 6, 01.06.2016, p. 938-948.

Research output: Contribution to journalArticle

@article{4e12da62f03945de80e51232b57746ab,
title = "Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody",
abstract = "The kinase receptor encoded by the Met oncogene is a sensible target for cancer therapy. The chimeric monovalent Fab fragment of the DN30 monoclonal antibody (MvDN30) has an odd mechanism of action, based on cell surface removal of Met via activation of specific plasma membrane proteases. However, the short half-life of the Fab, due to its low molecular weight, is a severe limitation for the deployment in therapy. This issue was addressed by increasing the Fab molecular weight above the glomerular filtration threshold through the duplication of the constant domains, in tandem (DCD-1) or reciprocally swapped (DCD-2). The two newly engineered molecules showed biochemical properties comparable to the original MvDN30 in vitro, acting as full Met antagonists, impairing Met phosphorylation and activation of downstream signaling pathways. As a consequence, Met-mediated biological responses were inhibited, including anchorage-dependent and -independent cell growth. In vivo DCD-1 and DCD-2 showed a pharmacokinetic profile significantly improved over the original MvDN30, doubling the circulating half-life and reducing the clearance. In pre-clinical models of cancer, generated by injection of tumor cells or implant of patient-derived samples, systemic administration of the engineered molecules inhibited the growth of Met-addicted tumors.",
keywords = "Antibody, Cancer targeted therapy, Fab, Half-life, Met, Protein engineering",
author = "Simona Cignetto and Chiara Modica and Cristina Chiriaco and Lara Fontani and Paola Milla and Paolo Michieli and Comoglio, {Paolo M.} and Elisa Vigna",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.molonc.2016.03.004",
language = "English",
volume = "10",
pages = "938--948",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Dual Constant Domain-Fab

T2 - A novel strategy to improve half-life and potency of a Met therapeutic antibody

AU - Cignetto, Simona

AU - Modica, Chiara

AU - Chiriaco, Cristina

AU - Fontani, Lara

AU - Milla, Paola

AU - Michieli, Paolo

AU - Comoglio, Paolo M.

AU - Vigna, Elisa

PY - 2016/6/1

Y1 - 2016/6/1

N2 - The kinase receptor encoded by the Met oncogene is a sensible target for cancer therapy. The chimeric monovalent Fab fragment of the DN30 monoclonal antibody (MvDN30) has an odd mechanism of action, based on cell surface removal of Met via activation of specific plasma membrane proteases. However, the short half-life of the Fab, due to its low molecular weight, is a severe limitation for the deployment in therapy. This issue was addressed by increasing the Fab molecular weight above the glomerular filtration threshold through the duplication of the constant domains, in tandem (DCD-1) or reciprocally swapped (DCD-2). The two newly engineered molecules showed biochemical properties comparable to the original MvDN30 in vitro, acting as full Met antagonists, impairing Met phosphorylation and activation of downstream signaling pathways. As a consequence, Met-mediated biological responses were inhibited, including anchorage-dependent and -independent cell growth. In vivo DCD-1 and DCD-2 showed a pharmacokinetic profile significantly improved over the original MvDN30, doubling the circulating half-life and reducing the clearance. In pre-clinical models of cancer, generated by injection of tumor cells or implant of patient-derived samples, systemic administration of the engineered molecules inhibited the growth of Met-addicted tumors.

AB - The kinase receptor encoded by the Met oncogene is a sensible target for cancer therapy. The chimeric monovalent Fab fragment of the DN30 monoclonal antibody (MvDN30) has an odd mechanism of action, based on cell surface removal of Met via activation of specific plasma membrane proteases. However, the short half-life of the Fab, due to its low molecular weight, is a severe limitation for the deployment in therapy. This issue was addressed by increasing the Fab molecular weight above the glomerular filtration threshold through the duplication of the constant domains, in tandem (DCD-1) or reciprocally swapped (DCD-2). The two newly engineered molecules showed biochemical properties comparable to the original MvDN30 in vitro, acting as full Met antagonists, impairing Met phosphorylation and activation of downstream signaling pathways. As a consequence, Met-mediated biological responses were inhibited, including anchorage-dependent and -independent cell growth. In vivo DCD-1 and DCD-2 showed a pharmacokinetic profile significantly improved over the original MvDN30, doubling the circulating half-life and reducing the clearance. In pre-clinical models of cancer, generated by injection of tumor cells or implant of patient-derived samples, systemic administration of the engineered molecules inhibited the growth of Met-addicted tumors.

KW - Antibody

KW - Cancer targeted therapy

KW - Fab

KW - Half-life

KW - Met

KW - Protein engineering

UR - http://www.scopus.com/inward/record.url?scp=84974814468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974814468&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2016.03.004

DO - 10.1016/j.molonc.2016.03.004

M3 - Article

AN - SCOPUS:84974814468

VL - 10

SP - 938

EP - 948

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 6

ER -